P. Friedl and colleagues. The study evaluated 313 stage I–III patients from the SUCCESS-A trial using the Guardant Reveal tissue-free epigenomic assay, yielding a positive predictive value of 94% for subsequent relapse.
Evaluating Tissue-Free Epigenomic Assays in Early Breast Cancer
Traditional tumour-informed panels require archival tissue, bespoke design, and lengthy turnaround times. According to Kefah Mokbel, Chair of Breast Cancer Surgery at the London Breast Institute, a tissue-free assay removes all three hurdles, making population-level surveillance plausible. The Friedl et al. analysis utilized blood draws roughly two years post-chemotherapy to spot minimal residual disease without prior sequencing of the patient’s primary tumor tissue.
Did you know? Traditional molecular residual disease (MRD) testing often relies on customized assays built from surgically removed tumor tissue, which can delay testing timelines and complicate logistics in routine clinical practice.
Key Findings and Statistical Metrics from the SUCCESS-A Analysis
Out of the 313 patients evaluated in the study, circulating tumor DNA was detected in 18 individuals, representing 5.8% of the cohort, as reported by Friedl and colleagues. Among those 18 positive cases, 17 subsequently developed distant recurrence, establishing a positive predictive value of 94%.
The median lead time between the positive test and clinical relapse reached 7.9 months. Survival metrics showed significant hazard ratios for distant recurrence-free interval at 33.3 and overall survival at 27.3, though researchers noted that 18 events limit the precision of the wide confidence intervals.
Clinical Limitations and Cautions Regarding Post-Treatment ctDNA
Despite the high positive predictive value, experts urge caution regarding the current clinical utility of post-treatment blood draws. According to Kefah Mokbel, prognostic information does not automatically equal actionable treatment. No completed randomized trials currently show that intervening based on minimal residual disease detection alters survival outcomes.
Furthermore, the sensitivity of 73% applied strictly to samples drawn within 12 months of recurrence, dropping lower across the entire cohort. Because the assay functions primarily as a rule-in test, a negative result offers no clinical reassurance, particularly for estrogen receptor-positive breast cancer, which can recur over decades and typically sheds lower levels of tumor DNA.
Ongoing Clinical Trials Addressing Actionability
Ongoing research aims to bridge the gap between detection and clinical intervention. Trials such as DARE, ZEST, and TRAK-ER are designed to answer whether acting on positive circulating tumor disease markers can successfully change patient survival outcomes. Until these randomized studies report results, a positive test primarily shortens the window of uncertainty rather than providing an immediate targeted intervention.
Frequently Asked Questions
What is a tissue-free epigenomic assay?
Unlike tumor-informed tests that require sequencing from a patient’s original surgical tissue, a tissue-free assay analyzes blood plasma directly for specific epigenetic signatures, such as methylation patterns, without needing prior knowledge of the primary tumor’s genomic profile.
Does a negative ctDNA test mean a patient is cured?
No. According to published analyses, tissue-free liquid biopsies act as rule-in tests with high specificity, meaning a positive result strongly predicts recurrence, but a negative result does not rule out hidden or sub-threshold disease.
Are there treatments available for patients with positive post-chemotherapy ctDNA?
Currently, detecting minimal residual disease is prognostic rather than actionable. Clinical trials are underway to determine if early therapeutic interventions change survival for patients testing positive.
To stay informed on the latest breakthroughs in oncology research and clinical trials, subscribe to our newsletter or explore our archive of cancer research updates.
Keep reading